Clinical trial B1931030
A phase 4, open label, randomized study of two Inotuzumab Ozogamicin dose levels in adult patients with relapsed or refractory b cell acute lymphoblastic leukemia eligible for hematopoietic stem cell transplantation and who have risk factor(s) for veno occlusive disease
| Cancers | |
|---|---|
| Organ | Acute leukemia |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 4 |
| Academic trial | Non |
| Sponsor | Pfizer |
| EudraCT Identifier | 2018-001557-27 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03677596 |
| Inclusion criteria | Relapsed or refractory precursor CD22-positive B-cell ALL and who are eligible for HSCT - Have 1 or more of the following risk factors for developing VOD: a. Due to receive Salvage 2 or greater; b. Prior HSCT;c. Age >=55 years |
| Last update |